402-TCR

N/A

Report date: 2025/04/10 16:18:57

Base Information

Drug Name402-TCR
Drug Alias Name402-TCR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesT-Cure Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesT-Cure Bioscience Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsLiver Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A